

Dear Editor,

Thank you for carefully reviewing our manuscript previously titled “**Allogeneic hematopoietic stem cell transplantation in a 3-year-old boy with congenital pyruvate kinase deficiency: A case report**” for possible publication in the *World Journal of Clinical Cases*. We are grateful to you and your reviewers for their constructive critique. We have revised the manuscript, highlighting our revisions in red. and have attached point-by-point responses detailing how we have revised the manuscript in response to the reviewers' comments below.

Thank you for your consideration and further review of our manuscript. Please do not hesitate to contact us with any further questions or recommendations.

Yours Sincerely,

**Xue Yang, MS**, Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China; Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu 610041, Sichuan Province, China.  
xueyang@scu.edu.cn

## **Reviewer Comments:**

### **Reviewer #1:**

*1. Major points The manuscript includes only a table with the analytics of the at birth, 12-days-old and 2-months-old, with very short information about the last two times. A more extensive information about the analytics, as well as other clinical analyses should be included. Moreover, in this table or in an additional one data the pre-transplant situation of the patient and the follow up after transplantation (1 month, 2 month and 6 month post-transplant, or so) should be included as well.*

### **Response:**

We have added another table (Table 2) about the pre-transplant situation of the patient and the follow up after transplantation (1 month, 2 month and 6 month post-transplant).

*2. A detailed discussion of this additional table should be included in the results chapter In the discussion chapter, a long text discussing the potential similarities between PKD and Thalassemia is included. This part is not clearly written and should be rephrased and re-oriented.*

### **Response:**

We have discussed the above content according to the reviewers' opinions and added Table 3 to discuss the potential similarities between PKD and Thalassemia in included.

*3. The name of the patient appears in different parts of the text. Taking into account the rules of the Data Protection Act in the different countries, the name and any information related with the personal identification of the patient and relatives should be removed from the text.*

**Response:**

We have removed the name of this patient.

*4. In general, the whole text needs to be improved because there are many language mistakes, typing errors. In addition, the case presentation should be written in past tense. Now, the text is a mixture of present and past. Minor points Data are reflected in different units at different parts of the text. Hemoglobin is shown as g/dL and also as g/L. Thus, units should be homogenized as the most common use, g/dL in the opinion of this reviewer. HS are capitals that have not been expanded.*

**Response:**

We have carefully checked the content of the article and corrected the language mistakes and typing errors mentioned above as far as possible.

**Reviewer #2:**

*Pyruvate kinase deficiency is a kind of rare disease with limited therapeutic options and is currently treated mainly by blood transfusion support. PKD is a disease characterized by hemolytic anemia, and splenectomy is one of the effective treatments for transfusion-dependent patients aged 5 to 6 years or older. The 3-year-old patient reported in this paper had more severe anemia, was obvious transfusion-dependent, and was much younger. The author's team boldly borrowed from the treatment ideas of thalassemia and choose non-blood allogeneic hematopoietic stem cell transplantation to effectively help the patient overcome transfusion dependency, which provides new ideas for clinical treatment of this kind of patients and has a high meaning of practical reference. Therefore, I recommend acceptance of this manuscript.*

**Response:** Thank you for your comments.